Biological and conformational studies on analogues of a synthetic peptide enhancing HIV-1 infection. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Biological and conformational studies on analogues of a synthetic peptide enhancing HIV-1 infection.

J Pept Sci. 1998 Nov;4(7):436-48. Unique Identifier : AIDSLINE MED/99066696
Dettin M; Scarinci C; Zanotto C; Roncon R; De Rossi A; Di Bello C; Department of Chemical Process Engineering, University of Padua,; Italy. peptide@uxl.unipd.it

Abstract: We have previously demonstrated that a 23-amino acid peptide derived from the V3 loop of the surface glycoprotein of the HIV-1 strain MN is able to bind CD4 and to enhance HIV-1 infection. Further studies have suggested that the peptide/CD4 interaction induces an increase in both CD4 expression and CD4/gp120 binding affinity. This paper describes the biological and physico-chemical characterization of three analogues of reduced sequence that have been designed in order to identify the minimum active sequence of this peptide corresponding to the MN-HIV- 1 principal neutralizing domain. Biological studies indicate that the entire sequence is required for biological activity and that the sequence 1-18 presents an inhibitory activity. CD and FT-IR absorption data are discussed here in order to identify possible structure-function correlations.
Keywords: JOURNAL ARTICLE Amino Acid Sequence Cell Line/VIROLOGY Circular Dichroism Comparative Study Conserved Sequence Dose-Response Relationship, Drug Human HIV Envelope Protein gp120/*CHEMISTRY HIV-1/*PATHOGENICITY Molecular Sequence Data Peptide Fragments/*CHEMISTRY/*PHARMACOLOGY Protein Conformation Spectroscopy, Fourier Transform Infrared Structure-Activity Relationship Support, Non-U.S. Gov'tKWDjournalarticleaminoacidsequencecellline/virologycirculardichroismcomparativestudyconservedsequencedose-responserelationship,drughumanhivenvelopeproteingp120/KWDchemistryhiv-1/KWDpathogenicitymolecularsequencedatapeptidefragments/KWDchemistry/KWDpharmacologyproteinconformationspectroscopy,fouriertransforminfraredstructure-activityrelationshipsupport,non-uKWDsKWDgov't
990530
A9950912

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .